STRYKER CORPORATION Reports Q4 FY2022 Revenue of $563M and Net Income of $5.2B, Down 15% and Up 10.7%, Respectively.
March 6, 2023
Earnings report
Stryker Corporation ($NYSE:SYK), a medical technology company, recently reported their financial results for the fourth quarter of the fiscal year 2022, ending December 31 2022. On January 31, 2023, the company reported total revenue of USD $563.0 million and net income of USD $5202.0 million. This represented a decrease of 15.0% in total revenue and an increase of 10.7% in net income, compared to the same quarter a year earlier. Stryker Corporation has a long history of producing innovative medical technology and providing advanced products and services to customers around the world. The company has a wide range of products and services, from orthopedic implants, endoscopy equipment, and power tools to innovative software and other medical technologies.
The fourth quarter financial results demonstrate that the company is continuing to develop and introduce new products and services in order to meet customer needs and remain competitive in an ever-evolving healthcare industry. Overall, it appears that Stryker Corporation has done well in the fourth quarter of the fiscal year 2022. Despite a slight decrease in total revenue, net income increased significantly, indicating the company’s ability to maintain profitability in spite of challenging economic conditions. This encouraging result indicates that Stryker Corporation is well-positioned to continue its successful operations and remain competitive for many years to come.
Stock Price
On Tuesday, STRYKER CORPORATION reported Q4 FY2022 revenue of $563 million, a 15% decrease compared to the same quarter of the previous year. The company’s stock opened at $249.1 and closed at $253.8, up by 1.7% from the previous closing price of 249.5. Despite the lower revenue and higher net income, the company’s performance was seen as favorable by investors, as evidenced by the stock’s closing price. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Stryker Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 18.45k | 2.36k | 13.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Stryker Corporation. More…
| Operations | Investing | Financing |
| 2.62k | -2.92k | -749 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Stryker Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 36.88k | 20.27k | 43.5 |
Key Ratios Snapshot
Some of the financial key ratios for Stryker Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 7.4% | 1.5% | 16.5% |
| FCF Margin | ROE | ROA |
| 11.0% | 11.5% | 5.2% |
Analysis
At GoodWhale, we’ve conducted a detailed analysis of STRYKER CORPORATION’s fundamentals. Our Risk Rating shows that STRYKER CORPORATION is a medium risk investment in terms of financial and business aspects. We have also identified one risk warning in the company’s balance sheet, but to get more details, you need to be a registered user on our platform. With our comprehensive analysis of the data, you can make an informed decision when it comes to investing in STRYKER CORPORATION. More…
Peers
Stryker Corporation is one of the world’s largest medical technology companies. It offers a broad range of products including orthopedic implants, surgical instruments, medical equipment and software solutions. The company operates in over 100 countries and has a strong presence in the United States, Europe and Asia. Stryker’s competitors include Fukuda Denshi Co Ltd, Nihon Kohden Corp and Shanghai Sanyou Medical Co Ltd.
– Fukuda Denshi Co Ltd ($TSE:6960)
Fukuda Denshi Co. Ltd., together with its subsidiaries, manufactures and sells medical electronic equipment in Japan and internationally. The company operates through five segments: Diagnostic Cardiology, Diagnostic Imaging, Patient Monitoring, Electrotherapy, and Others. It offers diagnostic cardiology products, including electrocardiographs, stress test systems, Holter systems, ambulatory blood pressure monitors, and medical printers; and diagnostic imaging products comprising X-ray diagnostic systems, computed tomography systems, magnetic resonance imaging systems, ultrasound diagnostic systems, X-ray angiography systems, and nuclear medicine diagnostic systems. The company also provides patient monitoring products, such as central station systems, telemetry systems, patient monitors, and related accessories; electrotherapy products, such as shortwave diathermy machines and physical therapy equipment; and other products, such as endoscopic and ophthalmologic equipment. It sells its products primarily to general hospitals, clinics, and other health care facilities. The company was founded in 1930 and is headquartered in Tokyo, Japan.
– Nihon Kohden Corp ($TSE:6849)
Nihon Kohden Corp. is a Japanese manufacturer of medical equipment, headquartered in Tokyo. The company was founded in 1952 and has since grown to become a leading supplier of medical equipment in Japan. Nihon Kohden’s product lineup includes everything from patient monitors and electrocardiographs to ultrasound machines and medical robotics. The company also offers a wide range of services, including maintenance and repair services for its products.
Nihon Kohden has a market capitalization of 269.63 billion as of 2022. The company’s return on equity is 11.49%. Nihon Kohden is a leading manufacturer of medical equipment in Japan. The company offers a wide range of products and services, including maintenance and repair services for its products.
– Shanghai Sanyou Medical Co Ltd ($SHSE:688085)
Shanghai Sanyou Medical Co Ltd is a medical company with a market cap of 6.32B as of 2022. The company’s return on equity is 8.85%. Shanghai Sanyou Medical Co Ltd is engaged in the research, development, manufacture, and sale of medical devices and equipment. The company’s products include medical imaging equipment, medical consumables, and medical disposables.
Summary
Stryker Corporation is an American medical technologies firm specializing in the development, manufacturing, and marketing of medical devices, instruments, and related services. An analysis of the company’s performance over the past year shows that Stryker has seen a significant increase in total revenues, while earnings per share and operating margins have remained stable.
Additionally, the firm’s operating cash flows are well ahead of expectations, with year-over-year growth of more than 15%. These strong fundamentals signify that Stryker Corporation is well-positioned to capitalize on current market conditions and deliver favorable returns in the near future. The firm also maintains a highly focused dividend policy, providing investors with a healthy return on investment. Overall, Stryker Corporation is well-positioned for further growth and looks like a great investment opportunity.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
